Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Shares Outstanding (Diluted Average): 2023-2025

Historic Shares Outstanding (Diluted Average) for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to $76.7 million.

  • CG Oncology's Shares Outstanding (Diluted Average) rose 14.28% to $76.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.7 million, marking a year-over-year increase of 14.28%. This contributed to the annual value of $62.5 million for FY2024, which is 1343.03% up from last year.
  • Latest data reveals that CG Oncology reported Shares Outstanding (Diluted Average) of $76.7 million as of Q3 2025, which was up 0.66% from $76.2 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Shares Outstanding (Diluted Average) registered a high of $76.7 million during Q3 2025, and its lowest value of $3.9 million during Q1 2023.
  • For the 3-year period, CG Oncology's Shares Outstanding (Diluted Average) averaged around $44.5 million, with its median value being $62.5 million (2024).
  • Data for CG Oncology's Shares Outstanding (Diluted Average) shows a peak YoY surged of 1,600.89% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows CG Oncology's Shares Outstanding (Diluted Average) stood at $4.3 million in 2023, then skyrocketed by 1,343.03% to $62.5 million in 2024, then grew by 14.28% to $76.7 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $76.7 million in Q3 2025, compared to $76.2 million in Q2 2025 and $76.2 million in Q1 2025.